DSM Biologics
6000, Royalmount Avenue
Montreal
Quebec
H4P 2T1
Canada
Tel: 514-341-9940
Fax: 514-341-7821
Website: http://www.dsm.com/
Email: info.biologics@dsm.com
About DSM Biologics
DSM Biologics, a business unit of DSM Pharmaceutical Products, is a leading provider of manufacturing technology & services to the biopharmaceutical industry. In addition to offering world-class biopharmaceutical manufacturing services, DSM Biologics has co-exclusive rights, along with Dutch biotech company Crucell N.V., to license the high-producing PER.C6® human cell line as a production platform for recombinant proteins and monoclonal antibodies. DSM Biologics' FDA-approved facility in Groningen, the Netherlands was established in 1986, and has a strong track record in using a broad range of cell lines (PER.C6®, CHO, hybridoma, etc.) in biopharmaceutical manufacturing, and has wide-range of experience using multiple manufacturing (batch, fed-batch and continuous perfusion) and purification techniques. The combination of the PER.C6 human cell line and DSM's manufacturing services provides companies with a turn-key biologic manufacturing solution reducing cost, risk and time to market.
For more information, please visit www.dsmbiologics.com.
U.S. Headquarters:
DSM Pharmaceutical Products 45 Waterview Blvd. Parsippany, N.J. 07054-1298 Phone: 973-257-8011 Email: info.dsmpharmaceuticals@dsm.com
Last Updated: 03-27-2006
49 articles about DSM Biologics
-
DSM Biologics Expands its Innovative Biomanufacturing Technology Portfolio With the Introduction of the New Kremer Method™
6/28/2011
-
DSM Biologics Reports a New Record Achievement with DSM's Proprietary XD(R) Process Technology with a CHO Cell Line Producing an Fc-fusion Protein:
2/9/2011
-
DSM Biologics and NKT Therapeutics Inc. Sign Contract for Lead Product Development and Manufacture
2/8/2011
-
DSM Biologics to Acquire Rhobust(TM) Technology from Upfront Chromatography
5/5/2010
-
DSM Biologics Announces Milestone Advancement of Yield-Boosting XD(R) Technology for Biomanufacturing
5/5/2010
-
DSM Biologics Announces Entering an Agreement with the Australian Governments to Build and Operate a Biopharmaceutical Manufacturing Facility in Brisbane
5/3/2010
-
DSM PTG Unveils Bionate(R) II PCU
10/21/2009
-
DSM Biologics Announces Yield Boosts of 5-10 Fold With XD(R) Technology for Mammalian Manufacturing Platforms
5/18/2009
-
DSM Biologics And Crucell N.V.l Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins
2/10/2009
-
DSM Biologics and Crucell N.V. Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins
2/10/2009
-
DSM Biologics and Crucell N.V. Announce PER.C6(R) Research License Agreement with GlaxoSmithKline
12/18/2008
-
DSM Biologics And Crucell N.V. Announce PER.C6(R) Research License Agreement with GlaxoSmithKline
12/18/2008
-
DSM Biologics And Crucell N.V. Announce PER.C6(R) License Agreement with CSL Limited
12/18/2008
-
NicOx SA Signs Agreement With DSM Biologics for the Commercial Manufacture of Naproxcinod Drug Substance
12/2/2008
-
DSM Biologics and Crucell N.V. Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter Ltd.
11/25/2008
-
DSM Biologics and Crucell N.V. Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter Ltd.
11/25/2008
-
DSM Biologics and Crucell N.V. Announce Another Key Achievement for PER.C6(R) Technology; Scale up of High-titer Fed-Batch Process to 250 Liters
9/29/2008
-
DSM Biologics and Crucell N.V. Announce Another Key Achievement for PER.C6(R) Technology
9/29/2008
-
DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody
8/12/2008
-
DSM Biologics and Crucell N.V. Sign Agreement with Avid Bioservices, Inc. to Serve as First Pre-Approved U.S. Contract Manufacturer of PER.C6(R) Cell Line Proteins
6/25/2008